New naloxone nasal spray at least doubles the dose

Hospital News

The Food and Drug Administration today approved a naloxone hydrochloride nasal spray to treat opioid overdoses that delivers 8 milligrams of naloxone, up from 2 mg or 4 mg in previously approved products. 
“Addressing the opioid crisis is a top priority for the FDA, and we will continue our efforts to increase access to naloxone and place this important medicine in the hands of those who need it most,” said Patrizia Cavazzoni, M.D., director of FDA’s Center for Drug Evaluation and Research. 

Articles You May Like

FEMA Advisory reminds groups of COVID-19 funding assistance available
Report calls for broader scope of practice for nurses, better support for equity, mental health
AHA releases latest episode in PowerPlay series featuring AMA CEO Madara
Chair File: Gratitude — This Week and Every Week — for Our Hospital Teams
Despite $64M net loss, Oak Street forecasts continued growth in 2021